Physician profile
Ronald A Squires
NPI 1558339804
$900.06
in general payments reported to CMS, 2019-2025
13 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130 · 2021: $16.75 · 2022: $117 · 2023: $286 · 2024: $79.95 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $636.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $155.41 | 2022-2024 | Enhertu |
| Organox LTD | $139.59 | 2025 | |
| Genentech, INC. | $131.20 | 2025 | Itovebi |
| Medtronic USA, INC. | $130.37 | 2019 | |
| Merck Sharp & Dohme LLC | $101.72 | 2022-2024 | Keytruda, Lynparza |
| Seagen INC. | $82.58 | 2022-2023 | Tukysa |
| Abbvie INC. | $35.79 | 2023-2024 | Strattice Reconstructive Tissue Matrix Bps |
| Myriad Genetic Laboratories, INC. | $32.57 | 2021-2023 | Myrisk |
| Stemline Therapeutics INC. | $21.85 | 2023 | Orserdu |
| Tersera Therapeutics LLC | $20.90 | 2023 | Zoladex |
| Genmab U.S., INC. | $18.56 | 2024 | Tivdak |
| Astrazeneca Pharmaceuticals LP | $15.62 | 2023 | Enhertu |
| Genentech USA, INC. | $13.90 | 2023 | Tecentriq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Squires listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.